Table 2.

Histologic and immunohistochemical features of the acinic cell carcinomas included in this study

Case	Pure vs mixed	Growth pattern	Cytoplasmic granules	Grade	TNP	LYS	TP53 mutation, p53 IHC	Ki67*	Sequence depth (capture and amplicon sequencing)	Somatic mutations (n)	Non-acinic component	Grade	TNP	LYS	TP53 mutation, p53 IHC	Ki67*	Sequence depth (capture and amplicon sequencing)	Somatic mutations (n)
Pure ACCs
12	pure	Microglandular	small	2	Y	+	WT, −	21%	107x	9
17	pure	Microglandular	small and coarse	1	Y	+	P250fs, −	15%	155x and 7,361x	8
Mixed ACCs
7	mixed	Clear cell	absent	1	Y	+	R273C, +	25%	157x and 6,044x	2	IDC-NST	2	Y	+	NP, +	NP	NP	NP
9	mixed	Microglandular	small and coarse	1	Y	+	M237I, +	12%	653x and 7,066x	4	IDC-NST	3	Y	+	M237I,+	53%	231x and 6,876x	7
10	mixed	Microglandular	small	1	Y	+	R273H, +	22%	339x and 7,537x	5	IDC-NST	3	Y	+	NP, +	NP	NP	NP
14	mixed	Microglandular	small and coarse	1	Y	+	R273C, +	14%	357x and 7,745x	4	IDC-NST	3	Y	−	WT, −	92%	818x and 7,182x	12
	mixed	Microglandular	small and coarse	2			R273C, +	27%	478x and 7,425x	6
15	mixed	Microglandular	small	1	Y	+	S303fs, −	12%	285x and 7,269x	4	IDC-NST	3	Y	−	WT, −	33%	237x and 7,286x	3
16	mixed	Microglandular	small	1	Y	+	V157D, +	11%	218x and 6,906x	11	MBC	3	Y	−	V157D, +	44%	130x and 7,448x	7
	mixed	Clear cell	absent	2			V157D, +	19%	358x and 7,200x	8

IDC-NST, invasive ductal carcinoma of no special type; LYS, lysozyme; MBC, metaplastic breast carcinoma; NP, not performed; TNP, triple-negative phenotype (i.e. estrogen receptor-, progesterone receptor- and HER2-negative); WT, wild-type; Y, yes; +, positive; −, negative;

^*hotspot areas were selected.